Prevent the development of chemoresistance.
Decrease the effective dose of chemotherapy, reducing negative side effects.
Resensitize chemoresistant tumors that have already become resistant to chemotherapy.
The Details: How It Works
Through utilizing a common biomarker found in multiple types of chemoresistant cancers, Chemosense has developed a novel therapy that specifically targets and blocks receptors that promote and maintain chemoresistance. Through repurposing drugs already used in other areas of the clinic to target these receptors, this new therapy cuts to the core of chemoresistance, sensitizing tumors to the tumor shrinking effects of chemotherapy.
Grant and Contract Awards
Boyang Wu (PI) – College of Pharmacy & Pharmaceutical Sciences: “The SEMA3E-Plexin D1-NRP2 Triad in Enzalutamide Resistance and Neuroendocrine Prostate
2020 ASCO Abstract
Repurposing antimuscarinics to treat lethal chemoresistant prostate and lung cancers.Download
2019 AACR Annual Meeting Poster
CHRM1-mediated acetylcholine signaling protects prostate cancer cells from the chemotherapy agent docetaxel.Download